Preclinical research revealed that combining endostar with an anti-PD-1 antibody yielded potent synergistic effects, suppressing Lewis lung carcinoma growth through tumor microenvironment amelioration and autophagy induction (27). This evidence concerns the gene PDCD1 and neoplasm.